Recognizing a helical form of amyloid‑beta in Alzheimer’s
Recognition of Abeta monomeric helix
Researchers are developing a helical peptide that binds single amyloid‑beta proteins to prevent and break up the toxic clumps that harm people with Alzheimer’s disease.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of South Florida NIH-funded |
| Lab location | 1 site (Tampa, United States) |
| Project ID | NIH-11250005 on NIH RePORTER |
What this research studies
This project focuses on a new type of small protein‑like molecule (a helical peptidomimetic) that locks individual amyloid‑beta molecules into a harmless shape. In lab and mouse experiments these molecules both stopped amyloid from forming toxic fibrils and disrupted existing plaques, and they improved nerve‑cell growth without obvious toxicity. The team has seen plaque reduction in Alzheimer’s model mice but the work is still preclinical and has not yet been tested in people. If you have Alzheimer’s or care for someone who does, this approach aims to neutralize the protein clumps that contribute to brain cell damage.
Who could benefit from this research
Good fit: Ideal candidates for eventual clinical trials would be people with early‑stage Alzheimer’s disease or mild cognitive impairment linked to amyloid pathology.
Not a fit: People whose dementia is not driven by amyloid pathology or those with very advanced disease where plaque removal is unlikely to restore function may not benefit.
Why it matters
Potential benefit: If successful, this approach could both prevent and dissolve amyloid plaques, protecting neurons and potentially slowing cognitive decline in people with Alzheimer’s.
How similar studies have performed: Monoclonal antibodies like aducanumab have shown plaque removal but with safety concerns, while helical peptidomimetics are a newer, largely preclinical strategy with promising animal results but limited human data.
Where this research is happening
Tampa, United States
- University of South Florida — Tampa, United States (Active)
Researchers
- Principal investigator: Cai, Jianfeng — University of South Florida
- Study coordinator: Cai, Jianfeng
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.